A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma

2024-519499-22-00 Human pharmacology (Phase I) - First administration to humans Ongoing, recruiting

Start 4 Aug 2025 · Status Ongoing, recruiting · 1 EU/EEA countries · 3 sites

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruiting
Participants planned 158
Countries 1
Sites 3

Advanced or Metastatic Hepatocellular Carcinoma

Key facts

Sponsor
Alnylam Pharmaceuticals Inc.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
4 Aug 2025 → ongoing
Decision date (initial)
2025-06-27
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2024-519499-22-00
ClinicalTrials.gov
NCT06600321

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Advanced or Metastatic Hepatocellular Carcinoma

VersionLevelCodeTermSystem organ class
20.0 PT 10073071 Hepatocellular carcinoma 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Alnylam Pharmaceuticals Inc.

Sponsor organisation
Alnylam Pharmaceuticals Inc.
Address
300 3rd Street
City
Cambridge
Postcode
02142-1103
Country
United States

Scientific contact point

Organisation
Alnylam Pharmaceuticals Inc.
Contact name
Alnylam Clincial Trial Information Line

Public contact point

Organisation
Alnylam Pharmaceuticals Inc.
Contact name
Alnylam Clincial Trial Information Line

Locations

1 EU/EEA country · 3 investigational sites

By country

CountryMS statusPlanned subjectsSites
Italy Ongoing, recruiting 31 3
Rest of world
United States, Korea, Republic of
127

Investigational sites

Italy

3 sites · Ongoing, recruiting
Centro Ricerche Cliniche Di Verona S.r.l.
Oncology Unit, Piazzale Ludovico Antonio Scuro 10, 37134, Verona
Humanitas Mirasole S.p.A.
Operative unit of Oncology and Hematology, Via Alessandro Manzoni 56, 20089, Rozzano
Ospedale San Raffaele S.r.l.
U.O. Oncologia Medica unità di Fase I, Via Olgettina 60, 20132, Milan

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Italy 2025-08-04 2025-10-29

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-03-28 Italy Acceptable
2025-06-18
2025-06-27
2 SUBSTANTIAL MODIFICATION SM-1 2025-11-19 Italy Acceptable
2026-01-08
2026-01-29
3 SUBSTANTIAL MODIFICATION SM-2 2026-03-12 Italy Acceptable
2026-04-07
2026-04-28